J&J reports Tremfya demonstrates superiority versus Stelara in Crohn’s trial

Johnson & Johnson announced the first Phase 3 results for Tremfya in adult patients with moderately to severely active Crohn’s disease, which demonstrated superiority of both subcutaneous maintenance doses versus placebo and ustekinumab. Data showed that both maintenance doses of Tremfya met the composite co-primary endpoints compared to placebo in each individual study. In results versus ustekinumab, both doses of Tremfya demonstrated statistically significant and clinically meaningful differences on all prespecified pooled endoscopic endpoints. These findings were featured as a late-breaking oral presentation at Digestive Disease Week, or DDW, J&J noted. “The Phase 3 GALAXI program, comprised of two rigorous, double-blind studies with secondary endpoints comparing TREMFYA to ustekinumab, reiterate our dedication to addressing the needs of patients with Crohn’s disease and our deep scientific expertise in inflammatory bowel disease and focused innovation in the IL-23 pathway. These findings demonstrate the promise of TREMFYA for patients living with moderately to severely active Crohn’s disease compared to conventional and advanced therapies,” said David Lee, M.D., Ph.D., Global Therapeutic Area Head Immunology, Johnson & Johnson Innovative Medicine.